{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:26:02Z","timestamp":1785522362478,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Tanabe Pharma Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40744-026-00870-1","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:59:11Z","timestamp":1782147551000},"page":"1191-1202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in a Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT Study)"],"prefix":"10.1007","volume":"13","author":[{"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzo","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Masamune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6070-584X","authenticated-orcid":false,"given":"Hirokazu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"870_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMra1104650","volume":"366","author":"JH Stone","year":"2012","unstructured":"Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366:539\u201351.","journal-title":"N Engl J Med"},{"key":"870_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.41120","volume":"72","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol. 2020;72:7\u201319.","journal-title":"Arthritis Rheumatol"},{"key":"870_CR3","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2665-9913(19)30017-7","volume":"1","author":"W Zhang","year":"2019","unstructured":"Zhang W, Stone JH. Management of IgG4-related disease. Lancet Rheumatol. 2019;1:e55-65.","journal-title":"Lancet Rheumatol"},{"key":"870_CR4","doi-asserted-by":"publisher","unstructured":"Masamune A, Sano T, Takikawa T, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2021. J Gastroenterol. 2026. https:\/\/doi.org\/10.1007\/s00535-026-02438-w.","DOI":"10.1007\/s00535-026-02438-w"},{"key":"870_CR5","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/rheumatology\/keae243","volume":"64","author":"L Keller-Sarmiento","year":"2025","unstructured":"Keller-Sarmiento L, Viapiana N, Lanzillotta M, et al. Increased prevalence of malignancies in patients with IgG4-related disease: implications for clinical care. Rheumatology (Oxford). 2025;64:1326\u201332.","journal-title":"Rheumatology (Oxford)"},{"key":"870_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13075-018-1567-2","volume":"20","author":"L Wang","year":"2018","unstructured":"Wang L, Zhang P, Wang M, et al. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther. 2018;20:65.","journal-title":"Arthritis Res Ther"},{"key":"870_CR7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/joim.12942","volume":"286","author":"Y Peng","year":"2019","unstructured":"Peng Y, Li JQ, Zhang PP, et al. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study. J Intern Med. 2019;286:542\u201352.","journal-title":"J Intern Med"},{"key":"870_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40744-025-00763-9","volume":"12","author":"ZS Wallace","year":"2025","unstructured":"Wallace ZS, Park JY, Serra E, et al. Burden of glucocorticoid use and risk of toxicities among patients with immunoglobulin-G4-related disease: a retrospective US-based claims study. Rheumatol Ther. 2025;12:547\u201360.","journal-title":"Rheumatol Ther"},{"key":"870_CR9","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39132","volume":"67","author":"A Khosroshahi","year":"2015","unstructured":"Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 2015;67:1688\u201399.","journal-title":"Arthritis Rheumatol"},{"key":"870_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41584-025-01240-x","volume":"21","author":"F Peyronel","year":"2025","unstructured":"Peyronel F, Della-Torre E, Maritati F, et al. IgG4-related disease and other fibro-inflammatory conditions. Nat Rev Rheumatol. 2025;21:275\u201390.","journal-title":"Nat Rev Rheumatol"},{"key":"870_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102564","volume":"95","author":"K Okazaki","year":"2025","unstructured":"Okazaki K, Ikeura T, Uchida K. Can we cure IgG4-related diseases? Curr Opin Immunol. 2025;95:102564.","journal-title":"Curr Opin Immunol"},{"key":"870_CR12","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.semarthrit.2020.01.010","volume":"50","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhao Z, Gao D, et al. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: a randomized clinical trial. Semin Arthritis Rheum. 2020;50:1513\u201320.","journal-title":"Semin Arthritis Rheum"},{"key":"870_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","volume":"74","author":"MN Carruthers","year":"2015","unstructured":"Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74:1171\u20137.","journal-title":"Ann Rheum Dis"},{"key":"870_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/MD.0b013e3182431ef6","volume":"91","author":"A Khosroshahi","year":"2012","unstructured":"Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012;91:57\u201366.","journal-title":"Medicine (Baltimore)"},{"key":"870_CR15","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejim.2019.12.029","volume":"74","author":"C Campochiaro","year":"2020","unstructured":"Campochiaro C, Della-Torre E, Lanzillotta M, et al. Long-term efficacy of maintenance therapy with rituximab for IgG4-related disease. Eur J Intern Med. 2020;74:92\u20138.","journal-title":"Eur J Intern Med"},{"key":"870_CR16","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00535-022-01891-7","volume":"57","author":"K Uchida","year":"2022","unstructured":"Uchida K, Okazaki K. Current status of type\u00a01 (IgG4-related) autoimmune pancreatitis. J Gastroenterol. 2022;57:695\u2013708.","journal-title":"J Gastroenterol"},{"key":"870_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B\u00a0cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36.","journal-title":"Exp Hematol Oncol"},{"key":"870_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.4161\/mabs.21338","volume":"4","author":"O Hammer","year":"2012","unstructured":"Hammer O. CD19 as an attractive target for antibody-based therapy. MAbs. 2012;4:571\u20137.","journal-title":"MAbs"},{"key":"870_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","volume":"23","author":"BAC Cree","year":"2024","unstructured":"Cree BAC, Kim HJ, Weinshenker BG, et al. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial. Lancet Neurol. 2024;23:588\u2013602.","journal-title":"Lancet Neurol"},{"key":"870_CR20","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","volume":"392","author":"RJ Nowak","year":"2025","unstructured":"Nowak RJ, Benatar M, Ciafaloni E, et al. A phase\u00a03 trial of inebilizumab in generalized myasthenia gravis. N Engl J Med. 2025;392:2309\u201320.","journal-title":"N Engl J Med"},{"key":"870_CR21","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","volume":"392","author":"JH Stone","year":"2025","unstructured":"Stone JH, Khosroshahi A, Zhang W, et al. Inebilizumab for treatment of IgG4-related disease. N Engl J Med. 2025;392:1168\u201377.","journal-title":"N Engl J Med"},{"key":"870_CR22","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/acr.23543","volume":"70","author":"ZS Wallace","year":"2018","unstructured":"Wallace ZS, Khosroshahi A, Carruthers MD, et al. An international multispecialty validation study of the IgG4-related disease Responder Index. Arthritis Care Res (Hoboken). 2018;70:1671\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"870_CR23","unstructured":"Japan Registry of Clinical Trials. A prospective observational study on the long-term effectiveness and safety of inebilizumab for IgG4-related diseases in the real world setting in Japan (4SigHT study). https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT1031250749. Accessed 2026 Feb 20."},{"key":"870_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14397595.2020.1859710","volume":"31","author":"H Umehara","year":"2021","unstructured":"Umehara H, Okazaki K, Kawa S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol. 2021;31:529\u201333.","journal-title":"Mod Rheumatol"},{"key":"870_CR25","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1097\/MPA.0000000000001443","volume":"49","author":"S Kawa","year":"2020","unstructured":"Kawa S, Kamisawa T, Notohara K, et al. Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2018: revision of Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2011. Pancreas. 2020;49:e13\u20134.","journal-title":"Pancreas"},{"key":"870_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/mr\/roae096","volume":"35","author":"M Kanda","year":"2025","unstructured":"Kanda M, Nagahata K, Moriyama M, et al. The 2023 revised diagnostic criteria for IgG4-related dacryoadenitis and sialadenitis. Mod Rheumatol. 2025;35:542\u20137.","journal-title":"Mod Rheumatol"},{"key":"870_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10157-021-02040-9","volume":"25","author":"T Saeki","year":"2011","unstructured":"Saeki T, Kawano M, Nagasawa T, et al. Correction to: validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version. Clin Exp Nephrol. 2011;25:443\u20134.","journal-title":"Clin Exp Nephrol"},{"key":"870_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/jhbp.913","volume":"28","author":"T Nakazawa","year":"2021","unstructured":"Nakazawa T, Kamisawa T, Okazaki K, et al. Clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020: revision of the clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2021;28:235\u201342.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"870_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10384-024-01072-4","volume":"68","author":"M Takahira","year":"2023","unstructured":"Takahira M, Goto H, Azumi A. The 2023 revised diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Ophthalmol. 2023;68:293\u2013301.","journal-title":"Jpn J Ophthalmol"},{"key":"870_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.resinv.2023.06.009","volume":"61","author":"T Handa","year":"2023","unstructured":"Handa T, Matsui S, Yamamoto H, et al. The 2022 revised diagnostic criteria for IgG4-related respiratory diseases. Respir Investig. 2023;61:755\u20139.","journal-title":"Respir Investig"},{"key":"870_CR31","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1253\/circj.CJ-24-0026","volume":"88","author":"I Mizushima","year":"2024","unstructured":"Mizushima I, Morikage N, Ito E, et al. Validation of the diagnostic criteria for IgG4-related periaortitis\/periarteritis and retroperitoneal fibrosis (IgG4PA\/RPF) 2018, and proposal of a revised 2023 version for IgG4-related cardiovascular\/retroperitoneal disease. Circ J. 2024;88:1679\u2013888.","journal-title":"Circ J"},{"key":"870_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/259408","author":"MN Carruthers","year":"2012","unstructured":"Carruthers MN, Stone JH, Deshpande V, Khosroshahi A. Development of an IgG4-RD responder index. Int J Rheumatol. 2012. https:\/\/doi.org\/10.1155\/2012\/259408.","journal-title":"Int J Rheumatol"},{"key":"870_CR33","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s40744-023-00593-7","volume":"10","author":"C Perugino","year":"2023","unstructured":"Perugino C, Culver EL, Khosroshahi A, et al. Efficacy and safety of inebilizumab in IgG4-related disease: protocol for a randomized controlled trial. Rheumatol Ther. 2023;10:1795\u2013808.","journal-title":"Rheumatol Ther"},{"key":"870_CR34","doi-asserted-by":"crossref","unstructured":"Tanaka Y. Inebilizumab, a novel anti-CD19 antibody for treatment of IgG4-related disease: an overview from clinical trials. Expert Opin Biol Ther. 2026;26(2):149\u2013155.","DOI":"10.1080\/14712598.2026.2634052"},{"issue":"5","key":"870_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001179","volume":"9","author":"S-H Kim","year":"2022","unstructured":"Kim S-H, Park NY, Kim KH, Hyun J-W, Kim HJ. Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e1179.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"870_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","volume":"21","author":"M Stockfelt","year":"2025","unstructured":"Stockfelt M, Teng YKO, Vital EM. Opportunities and limitations of B\u00a0cell depletion approaches in SLE. Nat Rev Rheumatol. 2025;21:111\u201326.","journal-title":"Nat Rev Rheumatol"},{"key":"870_CR37","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1016\/S2665-9913(24)00089-4","volume":"6","author":"I Jha","year":"2024","unstructured":"Jha I, McMahon GA, Perugino CA, et al. Sex as a predictor of clinical phenotype and determinant of immune response in IgG4-related disease: a retrospective study of patients fulfilling the American College of Rheumatology-European League Against Rheumatism classification criteria. Lancet Rheumatol. 2024;6:e460\u20138.","journal-title":"Lancet Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00870-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00870-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00870-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:14:29Z","timestamp":1785518069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00870-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["870"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00870-1","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yoshiya Tanaka reports receiving speaking fees and\/or honoraria from Chugai Pharmaceutical Co., Ltd., UCB, AbbVie, AstraZeneca, Eli Lilly, Boehringer Ingelheim, GlaxoSmithKline, Eisai, IQVIA, Daiichi-Sankyo, Otsuka Pharmaceutical, Taisho Pharmaceutical, Gilead Sciences, and Bristol Myers Squibb. Yoshiya Tanaka is an Editorial Board member of\n                      Rheumatology and Therapy\n                      ; Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript, nor any of the subsequent editorial decisions. Yuzo Kodama reports receiving speaking fees and\/or honoraria from Tanabe Pharma Corporation. Shingo Nakayamada reports receiving speaking fees and\/or honoraria from GlaxoSmithKline, Eli Lilly, Asahi Kasei, Bristol Myers Squibb, Otsuka Pharmaceutical, Eisai, AstraZeneca, AbbVie, Astellas Pharma, Tanabe Pharma, Janssen, Chugai Pharmaceutical, Taisho Pharmaceutical, Ayumi Pharmaceutical, Gilead Sciences, UCB, Pfizer, and Boehringer Ingelheim. Atsushi Masamune reports receiving speaking fees and\/or honoraria from Tanabe Pharma Corporation. Hirokazu Sato and Akiko Takahashi are employees of Tanabe Pharma Corporation. Junichiro Shibata is a researcher at TXP Medical Co., Ltd. Yusuke Takeshima has a service contract with TXP Medical Co., Ltd. for medical data analysis. Mitsuhiro Kawano reports receiving speaking fees and\/or honoraria from Tanabe Pharma Corporation.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Non-Profit Organization MINS Institutional Review Board (IRB ID 12000060) and, where required, by the institutional ethics committees of each participating site. A complete list of all ethics committees and their reference numbers is provided in Supplemental Material\u00a0\n                      \n                      . The study is conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Biological Research Involving Human Subjects (Japan). Written informed consent will be obtained from all participants prior to enrollment. The study is registered with the Japan Registry of Clinical Trials (jRCT1031250749 [\n                      \n                      ]).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}